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Abstract
Seven rounds of mass drug administration (MDA) have been administered in Leogane, Haiti, an area hyperendemic for
lymphatic filariasis (LF). Sentinel site surveys showed that the prevalence of microfilaremia was reduced to ,1% from levels
as high as 15.5%, suggesting that transmission had been reduced. A separate 30-cluster survey of 2- to 4-year-old children
was conducted to determine if MDA interrupted transmission. Antigen and antifilarial antibody prevalence were 14.3% and
19.7%, respectively. Follow-up surveys were done in 6 villages, including those selected for the cluster survey, to assess risk
factors related to continued LF transmission and to pinpoint hotspots of transmission. One hundred houses were mapped
in each village using GPS-enabled PDAs, and then 30 houses and 10 alternates were chosen for testing. All individuals in
selected houses were asked to participate in a short survey about participation in MDA, history of residence in Leogane and
general knowledge of LF. Survey teams returned to the houses at night to collect blood for antigen testing, microfilaremia
and Bm14 antibody testing and collected mosquitoes from these communities in parallel. Antigen prevalence was highly
variable among the 6 villages, with the highest being 38.2% (Dampus) and the lowest being 2.9% (Corail Lemaire); overall
antigen prevalence was 18.5%. Initial cluster surveys of 2- to 4-year-old children were not related to community antigen
prevalence. Nearest neighbor analysis found evidence of clustering of infection suggesting that LF infection was focal in
distribution. Antigen prevalence among individuals who were systematically noncompliant with the MDAs, i.e. they had
never participated, was significantly higher than among compliant individuals (p,0.05). A logistic regression model found
that of the factors examined for association with infection, only noncompliance was significantly associated with infection.
Thus, continuing transmission of LF seems to be linked to rates of systematic noncompliance.
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Introduction
Lymphatic filariasis (LF) is a mosquito-transmitted parasitic
disease that is ranked by the World Health Organization (WHO)
as a leading cause of permanent disability worldwide. LF affects an
estimated 120 million people in 81 countries, with over 1 billion,
or one-fifth of the world’s population, at risk for filarial infection
due to their exposure to infective larvae through the mosquito
vector [1]. LF causes debilitating genital disease (hydrocele) in an
estimated 25 million men and lymphedema or elephantiasis of the
leg in 15 million people, mostly women [2].
The Global Programme to Eliminate Lymphatic Filariasis
(GPELF) was established in 2000 with the goal of eliminating LF
as a public health problem worldwide by 2020. The programme is
centered on annual mass drug administrations (MDAs) which are
based on the community-wide distribution of albendazole plus
either diethylcarbamazine (DEC) or ivermectin to all those at risk
in an endemic community. These drug combinations suppress the
parasite in the blood, thereby reducing the transmission potential
of the parasite, and also kill a broad spectrum of intestinal worms
[3]. The WHO currently recommends mass treatment in settings
where the prevalence of antigenemia is $1%. [4] For endemic
countries, it is thought that 4–6 rounds of MDA, with at least
60–70% compliance, are adequate to interrupt transmission.
GPELF has scaled up impressively since it began. By the end of
2007, 48 countries had implemented elimination programs and
approximately 570 million people had been treated. [1] In Haiti,
the national program began in 2001 after a demonstration project
in the Leogane commune started in 2000. The program
conducted an initial LF infection survey by testing schoolchildren
for the presence of filarial antigen in each of the 133 communes in
the country. The results of this survey were compiled into an
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infection map [5]. Treatment of the hyperendemic communes
(.10% antigenemia in children) has been the highest priority of
the National Programme for Elimination of Lymphatic Filariasis
(NPELF). Annual MDA in Haiti was gradually scaled up between
2000–2005 in all hyperendemic communes, except those areas
where political instability in 2004–2005 threatened the safety of
distribution staff (e.g. Port au Prince and Gonaives). Because of an
interruption in funding there was no MDA in Haiti in 2006, but
MDA resumed in 2007.
The current benchmark for success, as defined by the WHO, is
a microfilaria prevalence of less than 1% in a community.
Microfilaremia is indicative of the presence of motile larvae of the
parasite (microfilariae) in the blood stream. If microfilaremia in a
community is less than 1%, it is thought that transmission of the
parasite cannot be sustained and there should be few or no
incident infections. In order to measure the effect of the MDAs on
transmission, and thus their effectiveness, surveys were conducted
at sentinel sites around Leogane commune [6]. In 2005, the
microfilaremia in Leogane was below 1%, reaching the WHO
benchmark for successful interruption of transmission [7]. In these
settings, current WHO guidelines recommend conducting cluster
surveys of young children (2–4 years) to confirm the interruption of
transmission and determine whether MDA can be halted [8]. In
the absence of transmission and after at least 5 rounds of MDA,
children under 5 years of age are expected to be antigen and
antibody-negative. In August 2007 a survey was conducted of
children 2–4 years of age, residing in Leogane. Blood samples for
antigen and antibody testing were obtained. The results of the
survey showed 14% antigen prevalence by ICT test and 19%
antibody prevalence in children ages 2–4 years (n = 304) (Donovan
et. al, unpublished data). These findings indicate that six rounds of
MDA have not been sufficient to interrupt transmission in
Leogane.
Although the WHO recommendations do not include moni-
toring of mosquito infection, information regarding the persistence
of infection in the mosquito population is useful in determining
whether transmission is ongoing. Persistence of filarial DNA in the
mosquito population could be an indication that transmission has
not been interrupted. The current study was designed to confirm
continuing transmission of LF using blood and mosquito
diagnostic tools and to analyze factors that may be contributing
to the continued transmission of LF in Leogane, including
population migration and systematic noncompliance.
Methods
Study Site
Surveys were conducted in Leogane, Haiti. Leogane is located
30 km west of the capital Port-au-Prince. Based on initial antigen
prevalence as high as 50%, Leogane commune was considered to
be highly endemic for LF. Seven rounds of MDA had been carried
out prior to the present surveys for which data were collected
between January 15 and February 19, 2008.
Study Design
Villages representing six communities were selected from those
that were surveyed in the August 2007 study. Four communities
with two or more antigen positive children out of ten tested
[Guinebeau (4 positive), Corail Lemaire (4 positive), Dampus (3
positive), and Leogane (2 positive)] and two communities with no
antigen positive children (Santo and Dufort) were selected for this
study. In each village, 100 houses were mapped using Personal
Digital Assistants (PDAs) (Dell, Round Rock, Texas) equipped
with GPS. Thirty houses and 10 alternates were chosen randomly
by the PDA program for the study. Residents of selected
households were interviewed using a standardized questionnaire
and blood samples were collected at night by fingerprick. Due to
low levels of literacy all participants were given explanations of the
study and gave their verbal consent to be interviewed and bled for
filarial testing. Consent was documented on the PDAs. For
children under the age of 12 years, parents or guardians gave the
consent. The study protocol was reviewed and approved by the
Institutional Review Board at the Centers for Disease Control and
Prevention and the Ethics Committee of Hopital Ste. Croix.
GPS Mapping and Sampling
Two teams surveyed each of the communities. Details of the PDA
and GPS programs are described elsewhere [9]. In Guinebeau,
Corail Lemaire, Dampus and Leogane, mapping started at a house
previously identified as having an antigen positive child, which was
designated as the index house. This house was mapped but not
considered for selection to participate in the study. In communities
with no antigen positive children in the previous survey (Santo and
Dufort), a house that was centrally located was randomly chosen.
The two teams each mapped 50 houses in opposite directions from
the index or centrally located house. The GPS data were
synchronized and 30 households and 10 alternates were chosen
by the GPS program to participate in the study. The 30 households
were visited first and if the residents from any household declined to
participate in the study, one of the alternate houses was chosen. An
attempt was made to revisit households where no one was home
before an alternate house was selected.
Questionnaire
A short questionnaire was developed for the PDAs using Visual
CE, as described elsewhere [9]. Each participant was asked to
provide demographic information (age, sex, birthplace) that was
recorded in the PDA. Individuals were asked questions regarding
travel, general knowledge of lymphatic filariasis, compliance with
previous MDAs and, if noncompliant, reasons for noncompliance.
In order to determine travel history, participants were asked if they
had left Leogane in the past, for how long and where they had
Author Summary
Lymphatic filariasis (LF) is a mosquito-borne parasitic
disease that affects an estimated 120 million people
worldwide with over 1 billion at risk for infection. LF is
considered to be a leading cause of permanent disability
worldwide due to the clinical manifestations of the
disease. A global effort was established to eliminate LF
by 2020 through interruption of transmission by annual
mass administrations of anti-parasitic drugs. In Leogane,
Haiti, seven rounds of drug administration have been
administered and, though infection levels have dropped,
transmission has not been interrupted. In this study the
authors examined factors that could contribute to
continuing transmission of LF in Haiti. Ongoing transmis-
sion was confirmed by high infection rates among young
children. Infection was found to cluster at the household
level within communities. The factor most associated with
this transmission was systematic noncompliance with drug
administration (i.e. never taking the medication). While
increased health education and awareness campaigns may
improve noncompliance, new tools and approaches may
be needed to stop transmission of LF in Haiti. Understand-
ing obstacles and solutions from the Haiti program could
aid elimination programs in other countries.
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traveled. For noncompliance, participants were asked if they had
ever participated in an MDA, if they had participated in the
previous MDA (2007) and the MDA before that (2005). Systematic
noncompliance was defined as never having participated in an
MDA. Unless otherwise stated, the term noncompliance refers to
systematic noncompliance. Participants were asked if they had
lived in Leogane their entire lives and if not, when they had moved
to Leogane. These questions were used to determine migration
into Leogane. Each completed survey was connected by the
household variable to the GPS coordinates for that house. For
children under 12 years of age, parents or guardians completed the
questionnaire for the children. Individuals responding to the
questionnaire were not prompted or coached in their responses.
Blood Collection
Residents of households that had been selected for interviews
were revisited in the evening (8–10 pm) and individuals older than
three years of age were asked to provide blood samples. High-flow
lancets (Becton Dickinson, Franklin Lakes, NJ) and EDTA coated
blood collection tubes (Ram Scientific Inc, Yonkers, NY) were
used to collect approximately 500 ml of blood from all consenting
individuals. Tubes were stored in coolers until samples were
processed the following day.
Antigen Analysis
Antigenemia was assessed by two methods, ICT card (Binax,
Portland, OR) and Og4C3 ELISA (TropBio, Townsville,
Australia). Briefly, the day after blood collection, 100 ml of blood
was added to the sample pad of an ICT card and read at 10
minutes according to manufacturer’s instructions. Two lines in the
viewing window of the card indicated a positive result [10].
Additional blood (60 ml per disk in 10 ml spots) was pipetted onto
Trop Bio filter paper for shipment back to the CDC laboratory.
Og4C3 antigen analysis was completed by diluting three blood
spots per patient into 200 ml of dilution buffer and using the
Og4C3-ELISA kit. Analyses were performed per manufacturer’s
instructions.
Microfilaremia Analysis
For samples positive for antigen by ICT test, 60 ml of blood was
pipetted on to microscope slides in three lines of 20 ml each. The
slides were dehemaglobinized, fixed, stained with Giemsa stain
and read by trained laboratory technicians at Hopital Ste. Croix.
Antibody Analysis
Serum was eluted from filter paper blood spots to analyze the
antibody response to the Bm14 antigen by ELISA [11]. Briefly,
one blood spot per patient was eluted in 250 ml 0.05% PBS/
Tween overnight at 4uC. Immulon ELISA plates were coated with
recombinant Bm14 antigen at a concentration of 2 mg/ml in
bicarbonate buffer and incubated overnight at 4uC. The following
morning, plates were blocked for 1 hour at 4uC with 0.3% PBS/
Tween. Eluates from the blood spots were added to the plates and
incubated for 2 hours at room temperature. Biotinylated mouse
anti-human IgG4 (Zymed, San Francisco, CA) was diluted 1:1000
added to the plate and incubated for 1 hour at room temperature.
The streptavidin-alkaline phosphatase (Invitrogen, Carlsbad, CA)
was diluted 1:1000 and again incubated for 1 hour at room
temperature. Plates were washed in between each step with 0.05%
PBS/Tween. Plates were visualized using 4-nitrophenyl phosphate
disodium salt hexahydrate tablets (Sigma, St. Louis, MO) dissolved
in 10% diethanolamine (DEA) and read on a spectrophotometer
at 405 nm.
Mosquito Collection and Analysis
Five CDC gravid traps were randomly placed around each
community and the positions of the traps recorded with GPS.
Mosquitoes were collected for five consecutive nights. Recently-fed
vectors (blood-fed, gravid, or semi-gravid Culex quinquefasciatus)
from each trap location were sorted and pooled in tubes of 1- 20
mosquitoes. Males and non-vector species were discarded.
Mosquito pools were dried and shipped to the CDC. DNA was
extracted from the mosquito pools at Smith College using a metal-
bead vortex grinding technique [12] and a modified Qiagen
DNeasy extraction column protocol [13,14], followed by real-time
PCR detection of the W. bancrofti LDR sequence as previously
described [15]. Statistical analysis of the mosquito PCR results was
performed using the PoolScreen v.2.02 program, designed to
estimate the vector infection rate from pools of vectors [16].
Statistical Analysis
Unless otherwise stated all statistical analysis was done using
SAS version 9.1. The surveylogistic procedure was used to
determine which possible transmission factors were significantly
associated with filarial infection. This procedure was selected in
order to properly weight the analysis based on the sampling
design. The association between infection status and compliance
was assessed by the chi-square test. A chi-square test was
performed for each village and for the study area as a whole.
Infection status was determined using a composite variable based
on four tests for filarial infection. Global clustering of infected
households, as well as of noncompliant households, was assessed
by Cuzick and Edwards’ nearest neighbor analysis at 2, 3, 4, and 5
nearest neighbors [17]. Households were defined as infected if at
least one person in the household was positive for the various
measures defined in the results. A Simes correction was used to
control the overall type I error rate for multiple testing [18]. A
Chi-square goodness-of-fit test was also used to compare the
number of persons actually treated per household with the number
of persons expected to be treated per household given the overall
compliance rate in the village. The results of this test were used to
determine the randomness of noncompliance within a village.
Results
Community Characteristics
A total of 564 people were surveyed by questionnaire. Of those
who responded, a total of 455 (80.7%) people were tested for LF.
People were not tested for LF because of refusal to give blood, low
volumes of blood and loss to follow up. An average of 24
households per community were tested for LF of these, an average
of seven households were originally selected as alternates.
Reported age among tested individuals ranged from 3 to 95 years
of age with the median age in the communities ranging from 18 to
25. Characteristics for the population tested for LF in each
community are summarized in Table 1.
Filarial Infection Prevalence
Filarial infection was assessed by four different methods; antigen
detection by ICT card and Og4C3 ELISA; antibody detection by
Bm14 ELISA; and microfilaria (MF) detection by microscopy.
Blood films for microfilaremia were prepared only for individuals
positive by ICT, so the MF prevalence represents a minimum
value. Briefly, the minimum MF prevalence was 4.6% overall,
with MF prevalences ranging from 0–7.8%. Overall antigen
prevalence by ICT was 18.5%, with the highest prevalence in
Dampus (32.8%) and the lowest prevalence in Corail Lemaire
(2.9%). Overall antigen prevalence by Og4C3 test was 21.7%.
Non-Compliance with MDA for Filariasis
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Corail Lemaire again had the lowest antigen prevalence (5.1%),
however the rank of ICT prevalence and Og4C3 prevalence were
not identical for the other communities. Antibody prevalence, a
measure of exposure to the parasite, was 47.0% overall. The
highest antibody prevalence was found in Leogane at 72.4% and
the lowest was in Corail Lemaire at 26.5%. Complete results for
each community can by found in Table 2.
Age prevalence curves for all four infection measures are given
in Figure 1. There is an overall trend of increasing prevalence for
both antigen and antibody with age. The prevalence of MF was
lower than baseline but not below the 1% cut-off required to stop
MDA. Of note are the prevalences of infection by the different
measures in the 3–5 year olds. Antigen prevalence in this age
group was 13% by both antigen tests. Prevalence of MF was 4.3%
and antibody prevalence was 30.4%.
Filarial DNA Rates
Molecular xenomonitoring (MX) was performed using mosqui-
toes collected from each community except Corail Lemaire
(logistical reasons). The average mosquito pool size was approx-
imately 18 and the number of pools tested from each community
ranged from 47 – 67. The filarial DNA rate was calculated for
each community by the Poolscreen v.2.02 program (Table 3).
Filarial DNA rates were high in all communities tested, ranging
from 6.4% to 28%. Due to such high infection rates, and therefore
high percentage of positive pools, the 95% confidence intervals
were quite broad. The only significant difference in DNA rate was
seen between Dufort (6.4%) and the two communities with the
highest level of infection, Leogane (27%) and Dampus (28%).
Despite this lack of statistical difference, the pattern of mosquito
infection parallels the pattern of filarial infection with Dampus and
Leogane being the two communities with the highest levels of both
human and mosquito infection (Table 2).
Noncompliance
Compliance status was assessed by asking individuals if they had
ever taken a pill for filariasis. If they answered yes to that question,
they were asked if they had taken a pill for filariasis during the
more recent MDA or in prior MDAs. Of the 455 people who were
tested for LF, 109 (24%), reported never having taken a pill for
filariasis. One person did not respond to the question. Figure 2
illustrates the overall prevalence of systematic noncompliance
(never taken a drug for LF) and prevalence of systematic
noncompliance broken down by community. As with both human
and filarial DNA rates, Dampus had the highest prevalence of
systematic noncompliance at 42.2%. However, unlike human
infection prevalence, the second highest prevalence of systematic
noncompliance was in Corail Lemaire at 30.9%. This is contrast
to the human and mosquito infection data, where Corail Lemaire
had the lowest prevalence of both. The lowest prevalence of
systematic noncompliance was found in Dufort with 16.2%
corresponding with the lowest mosquito infection rate (6.4%).
Of the individuals who reported having taken a pill for filariasis
232 individuals (67.2%) reported being treated during the most
recent MDA (2007) and 272 individuals (79%), reported having
taking pills in 2005 or earlier. There was no MDA in Haiti during
2006.
In order to determine if noncompliance was associated with
infection, we first examined the prevalence of infection determined
by ICT card test in compliant and noncompliant individuals.
Figure 3 shows the infection prevalence in compliant and
noncompliant individuals. The overall infection prevalence was
significantly higher in noncompliant individuals (26.6%) as
compared with compliant individuals (15.7%) (p-value ,0.05).
Infection prevalence was also statistically higher in noncompliant
individuals (35.3%) than in compliant individuals in Guinebeau
(11.4%), (p,0.05) and in Dampus (48.1% among noncompliant
Table 2. Infection measures by community.
Community Min. MF Prevalence ICT Prevalence Og4C3 Prevalence* Bm14 Prevalence Filarial DNA Rate
Dufort 7.4% (5/68) 11.8% (8/68) 23.4% (15/64) 44.1% (30/68) 6.4% (1075)
Guinebeau 4.2% (4/96) 15.6% (15/96) 28.2% (26/92 35.4% (34/96) 11.5% (1202)
Santo 4.2% (3/72) 18.1% (13/72) 25% (17/68) 45.8% (33/72) 13.6% (706)
Dampus 7.8% (5/64) 32.8% (21/64) 26.9% (14/52) 56.3% (36/64) 27.9% (1064)
Leogane 4.6% (4/87) 28.7% (25/87) 19.1% (16/84) 72.4% (63/87) 26.7% (1128)
Corail Lemaire 0.0% (0/68) 2.9% (2/68) 5.1% (3/59) 26.5% (18/68) N/A
Overall 4.6% (21/455) 18.5% (84/455) 21.7% (91/419) 47.0% (214/455)
*A smaller number of individuals were tested by Og4C3 due to low sample volumes.
doi:10.1371/journal.pntd.0000640.t002
Table 1. Community characteristics of tested participants.
Community N Male Female Median Age No. Households Avg. number per household
Dufort 68 26 42 24 19 3.6
Guinebeau 96 36 60 22.5 27 3.6
Santo 72 25 47 23.5 23 3.1
Dampus 64 27 37 25 24 2.7
Leogane 87 26 61 18 24 3.6
Corail Lemaire 68 35 33 24.5 28 2.4
doi:10.1371/journal.pntd.0000640.t001
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persons vs. 21.6% among compliant persons, p-value ,0.05). An
increase in infection prevalence for noncompliant individuals was
also seen in Corail Lemaire, and Leogane; however these
differences were not statistically significant.
Those individuals who reported never having taken drugs for
LF were asked their reason for not taking the pills. Table 4 is a
compilation of the reasons individuals gave for not taking pills for
LF. The number one reason was given as ‘‘don’t know’’. The
second most common reason was ‘‘fear of side effects’’, followed by
‘‘not in Leogane during the MDA’’.
Factors Contributing to Continued Transmission
The factors examined in this study were migration to Leogane,
travel from Leogane, knowledge of LF and noncompliance with the
MDAs. In order to determine which variable(s) were significantly
related to infection, univariate logistic regression analysis, controlling
for village, was performed on the responses in the questionnaire. Of
all the factors in this study, only compliance status was significantly
related to infection as determined by ICT card test (p-value=0.004,
Table 5). Neither migration from areas outside of Leogane nor
travel outside of Leogane were significantly related to infection status
as only 3.5% of individuals tested had moved to Leogane and only
5.1% had traveled outside of Leogane in the past year.
Clustering and Spatial Analyses
Clustering of noncompliance by household was initially
analyzed by Chi-square goodness-of-fit test; there was no evidence
of clustering by household (data not shown).
Figure 1. Age prevalence curves based on the various infection measures. Data are summarized across all communities. MF=microfilaremia
ICT = filarial antigen detected by ICT card test. Og4C3 = ELISA assay to detect filarial antigen Bm14= filarial antibody ELISA.
doi:10.1371/journal.pntd.0000640.g001
Table 3. Molecular xenomonitoring (filarial DNA rates).
Community # Mosq # Pools Mean Pool Size # Pos. Pools Max. Likelihood Est 95% Confidence Interval*
Dufort 1075 55 19.5 40 6.4% 4.3%–9.1%
Guinebeau 1202 67 17.9 58 11.5% 8.1%–16.0%
Santo 706 47 15.0 39 13.6% 8.8%–20.3%
Leogane 1128 62 18.2 60 26.7% 14.9%–59.4%
Dampus 1064 58 18.3 57 27.9% 15.1%–60.6.%
Total 5175 289 17.9 254
*Calculated by the Likelihood Ratio Method.
doi:10.1371/journal.pntd.0000640.t003
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Spatial analysis was done using the Cuzick and Edwards’
nearest neighbors test. The number of antigen positive individuals
per household ranged from 0 (59.4% of households) to 7 (0.7%).
The number of non-compliant individuals per household ranged
from 0 (53.9%) to 7 (0.7%). 40.6% of households had at least one
antigen positive individual and 46.2% of households included at
Figure 2. Prevalence of systematic noncompliant individuals by community. Individuals were considered noncompliant if they had
reported never participating in MDA (i.e. systematic noncompliance).
doi:10.1371/journal.pntd.0000640.g002
Figure 3. Prevalence of infection in compliant and noncompliant persons by community. ICT card test was used to determine infection
prevalence. Noncompliant individuals were those who reported never participating in MDA. Compliant individuals were those who reported ever
haven taken a drug for LF. The asterisk indicates a p-value ,0.05. by Chi-square test.
doi:10.1371/journal.pntd.0000640.g003
Non-Compliance with MDA for Filariasis
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least one noncompliant individual. Table 6 gives the results of the
test for various household attributes. Using ICT positivity as a
measure of infection, there were more antigen positive households
among the two, three, four and five nearest neighbors than would
be expected by chance. These results indicate that from the two
nearest neighbors up to the fifth nearest neighbors there was
significant clustering of antigen positive households. For house-
holds with an antibody positive individual there was significant
clustering for the two nearest neighbors. There was no clustering
in households of noncompliance.
Discussion
In Haiti 7 rounds of MDA have been delivered to the commune
of Leogane, with a missed round of MDA in 2006. By 2005 MF
prevalence was below the ,1% threshold that the WHO
recommends for stopping MDA. However, subsequent studies in
children suggested that transmission was ongoing despite the
apparent success of the MDAs. The aim of this study was to
determine the transmission status of LF in Leogane and to
examine possible factors contributing to transmission in the area.
The levels of microfilaremia and antigenemia found in the
communities in this study (with the exception of Corail Lemaire)
indicate that transmission is still ongoing in Leogane. Only Corail
Lemaire had MF prevalence below the ,1% WHO threshold for
stopping MDA. Antigen prevalence by both the ICT and Og4C3
test in children 3–5 years of age was above 10%. If transmission
had been interrupted there should be little to no infection in this
age group as they were born after the MDAs started. In addition to
the high prevalence of microfilaremia and antigenemia in most of
the communities surveyed, there was a high rate of infection in
mosquitoes collected from those communities. The presence of a
significant number of infected mosquitoes further supports the
conclusion that transmission is ongoing. Although the MDA
rounds have succeeded in lowering the overall prevalence of LF
infection in Leogane, they have not succeeded in interrupting
transmission of the parasite. Initial projections for the LF
elimination predicted that 5–6 rounds of MDA would be sufficient
to interrupt the transmission cycle of the parasite [19]. Since
transmission was persistent in Haiti after more than the
recommended rounds of MDA, migration, knowledge of LF,
and noncompliance with MDA were considered as potential
factors for ongoing transmission.
Of the factors examined, only systematic noncompliance was
statistically associated with infection status. Noncompliance has
been previously reported in Haiti. After 3 rounds of MDA in
Leogane, 18.6% of adults surveyed had not participated in MDA
[20]. Talbot et al found levels of noncompliance around 25% after
4 years of MDA [21]. The overall noncompliance rate in this study
was very similar (24.2%). This noncompliance rate yields a
compliance rate of around 76%, which is consistent with the
WHO recommendation of .60–70% compliance for interruption
of transmission. In Leogane, this level of compliance with MDA
has not been adequate to interrupt transmission of LF.
These results suggest that a consistent proportion of the
population has not been mobilized to participate in MDA. Social
mobilization strategies employed by the program clearly are not
reaching this segment of the population. It is important to
acknowledge the limitations of questionnaire-based coverage
surveys. It is possible that people do not remember taking the
drug in previous years. Nonetheless, infection levels were
significantly higher in noncompliant individuals as compared to
compliant individuals, demonstrating a biologic correlate of the
nonparticipation of the respondents in MDA. High rates of
noncompliance maintain a reservoir of infection, which drives LF
transmission.
Systematic noncompliance has been examined as a factor in
MDA success in a number of different national elimination
programs. In Egypt the noncompliance rate was very low (7.4%)
and consequently, the program was able to successfully reduce
infection levels to a point where transmission was probably
interrupted [22]. Although residual infection rates were the highest
Table 4. Reasons for noncompliance.
Reason for Noncompliance Frequency of Answer
Don’t know 44
Fear of side effects 30
Not in Leogane during MDA 18
Taking other medication 7
Had side effects previously 5
Pregnant 2
Don’t like to take pills 2
The pills are bad 1
A total of 109 noncompliant, LF tested individuals were used in the analysis.
Multiple answers were not allowed.
doi:10.1371/journal.pntd.0000640.t004
Table 5. Potential factors for infection status.
Factor P-value Odds Ratio 95% CI
Sex 0.658 0.906 0.584–1.405
Age 0.089 1.010 0.998–1.022
Move to Leogane* 0.462 0.661 0.220–1.991
Travel** 0.206 1.764 0.732–4.250
Knowledge of LF 0.399 1.366 0.762–2.448
Knowledge of lymphedema 0.237 0.764 0.483–1.197
Knowledge of hydrocele 0.690 0.881 0.473–1.270
Treatment status 0.004 1.971 1.244–3.121
*A move was defined as anyone who had not lived in Leogane their entire life.
**An individual was considered to have traveled if they had been outside
Leogane within the last year.
doi:10.1371/journal.pntd.0000640.t005
Table 6. Nearest neighbor analysis for spatial association.
Household Attribute k=2* k=3 k=4 k=5
Antigen positive by ICT test 0.042 0.005 0.004 0.014
Antibody positive by Bm14 test 0.003 0.104 0.205 0.357
Non-compliant 0.382 0.267 0.245 0.105
*Nearest neighbor analysis of spatial association by household. A household
was considered positive if there is one positive individual in the household.
k = the number of nearest neighbors. Significant test results indicate clustering
of the tested variable. A Simes correction is used to control for the type I error
rate for multiple testing. Highlighted results are significant at a Simes correction
level using an alpha = 0.05.
159 households out of the 180 households sampled were used in this analysis
due participants refusing to be tested for LF. This led to households with
incomplete data, which were excluded from the analysis.
doi:10.1371/journal.pntd.0000640.t006
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in noncompliant individuals, the authors also observed a trend
towards reduced infection rates in those individuals, indicating the
possibility of a ‘‘herd treatment effect’’ as transmission levels
decline [22]. These results are very encouraging for the Global
Elimination Programme but they may not be transferable to
Leogane where the baseline prevalence rates of MF and
antigenemia were considerably higher than in Egypt. Also, the
mode of drug distribution is different. In Egypt, health workers go
door-to-door to distribute drugs, whereas in Haiti, community
distribution points are used. A much higher compliance rate was
seen with the door-to-door distribution in Egypt and that,
combined with the lower baseline infection rates, led to the
impressive results that were observed.
Other countries have experienced noncompliance rates more
similar to that of Haiti. The compliance rates in India have been
consistently low. In the southern state of Tamil Nadu compliance
rates ranged between 46% and 64% [23,24]. A 2005 study in
Tamil Nadu found that only 30% of the study cohort complied
with all six rounds of MDA and a study in Orissa state found 83%
of the population had received the drug but only 49.5% consumed
them [25,26]. The picture is similar in other areas of the world.
Recent studies in the Philippines and the Colombo district of Sri
Lanka found noncompliance rates of 30% and 28% [27,28].
However, it is important to distinguish between noncompliance for
a single or several MDA rounds and systematic noncompliance
(never taking a drug for LF). Sporadic noncompliance is
problematic as it may reflect faults in the distribution system or
education message of the MDA. However, if there is only sporadic
noncompliance, all individuals in a community will have been
treated at some point in time and the development of the ‘‘herd
treatment effect’’ referred to by El-Setouhy et al will likely lead to
an overall reduction in infection prevalence and interruption of
transmission. Systematically noncompliant individuals continue to
provide a reservoir of MF and perpetuate the transmission cycle.
This is illustrated in our study with the high rates of systematic
noncompliance, filarial infection and mosquito infection and the
significant association between systematic noncompliance and
filarial infection. Systematic noncompliance not only reflects
possible weak points in the MDA program but threatens to
undermine the program’s goal of eliminating LF by interrupting
transmission.
With similar rates of noncompliance in various countries, is
there an underlying determinant or determinants that influence
compliance with MDA? In the Philippines and India the perceived
benefit of the MDA was associated with compliance. Knowledge
of LF was found to be linked to MDA compliance in the
Philippines and in Haiti [27,29]. A KAP survey conducted in Haiti
in 2000 as well as follow-up survey in 2004 found that women
were more likely to be noncompliant [29]. This observation was
also made in India [23]. In Haiti, the difference in compliance
between the sexes was most likely due to the initial exclusion of
women of child-bearing age from albendazole treatment during
the first two rounds of MDA. This policy was reversed in 2002 and
no discrepancy in compliance status was seen between males and
females in our study. Other factors previously found to be
associated with compliance status were ability to swallow pills and
the perceived status of the interviewee in the community [21]. In
the current study, the majority of noncompliant individuals cited
‘‘Don’t know’’ as the reason for not participating in the MDA. The
second highest response was fear of side effects (Table 4). While
the side effects have reduced significantly in Leogane over the
course of the MDAs [30], there seems to be residual concern based
on the anticipation of side effects to the drugs. Equally as
important are the ‘‘Don’t know’’ respondents. Is this a proxy
response for ‘‘Don’t care’’ or is there some other determinant of
compliance status that is not being captured in this or previous
surveys? Averted cases of lymphedema and hydrocoele are hard to
quantify and since there is little direct evidence that the MDA
provides clinical relief for those chronic conditions, community
members may not perceive any benefit to participating in MDA.
Given that the age group with the highest noncompliance was 3–5
years of age, the de-worming effects of albendazole do not seem to
be a major driver for parents to have their children participate in
MDA. This could be due either to lack of exposure to messages
regarding the de-worming properties of albendazole or a lack of
understanding of these messages. Renewed health education
efforts could provide incentive to participate by emphasizing the
prevention of future lymphedema and hydrocele cases and the
benefits of de-worming from albendazole. While health education
messages were highly publicized at the beginning of the MDA
cycle, the de-worming effects of albendazole were not emphasized.
This added benefit could induce more individuals to participate,
especially mothers and their children.
The variability of infection levels between communities (Table 2)
emphasizes that infection is focal in nature, a reflection of poorly
understood differences in mosquito habitat and density as well as
host factors. There is previous evidence for spatial variation in LF
infection. Ramzy et al reported non-uniform infection in LF [31].
A study done in 2001 in Papua New Guinea found micro-spatial
heterogeneity in LF infection [32]. In Haiti, a 2003 study found
spatial clustering of antigen positivity and IgG1 positivity [33]. The
authors of that study concluded that the transmission dynamics of
LF in Leogane may vary over as small a distance as tens of meters.
Using any of several definitions of infection status (e.g. antigen
by ICT card or antibody positivity) we found evidence for
clustering of filarial infection by the nearest neighbor analysis
(Table 6). In contrast, noncompliance was not found to be spatially
clustered. Why noncompliance would be statistically related to
infection but not show the same spatial relationship as infection is
unclear. There may be a spatial relationship to noncompliance
that was not captured by this study, perhaps because of our
sampling design, and further investigation of this relationship is
warranted, specifically to determine the effect of a noncompliant
individual on the infection status of his/her neighbors.
Although noncompliance was the only factor that was
significantly related to infection in our study, it may not account
for all of the transmission seen in Leogane. Initial infection
prevalence, vector density, biting density and topography all play a
role in infection. In a 2008 paper that used statistical methods to
define the Risk of Infection Index (RII) based on community
microfilariae load (CMFL) and vector density per man-hour
(MHD), the authors concluded that transmission may continue in
areas where MF prevalence is low but vector density is high [34].
In such situations it may be cost effective to use vector control, in
contrast to areas of higher MF prevalence and low vector density
where MDA may be the more cost effective tool [34]. The
mosquito data collected in this study provides information about
infection rates but not about vector and/or biting density. It was
also not possible to make any conclusions about the vector-parasite
relationship from this study. Investigations examining the effect of
increases MF loads on vector survival have reported conflicting
results and the exact relationship between W. bancrofti and its Culex
vector is not clear [35]. Further studies are needed to examine
vector issues in Haiti in order to determine the impact of vector
ecologies on local transmission, and the nature of the parasite-
vector relationship. This additional knowledge would aid in
determining if vector control would be a cost effective measure to
interrupt transmission there.
Non-Compliance with MDA for Filariasis
www.plosntds.org 8 March 2010 | Volume 4 | Issue 3 | e640
Population migration was not found to be a significant
contributor to transmission in this study; however, this could be a
consequence of the timing of the study. It is thought that the
instability in Haiti between 2004 and 2005 led to a migration of
individuals out of affected areas such as Port-au-Prince to less
affected areas such as Leogane. Port-au-Prince has never undergone
MDA, and these individuals could have represented a reservoir of
infection. Since this study was undertaken several years after the
unrest many of those individuals could have returned to their place
of previous residence. If this scenario was true then these individuals
would not be captured in the study. Thus, population migration
may still be a factor in the ongoing transmission of LF in Leogane
but was not reflected in this analysis.
An added factor contributing to transmission of LF is the missed
round of MDA in Haiti in 2006. A study conducted in September
2007 by Won et al argued that this missed round of MDA was
responsible for a rebound in infection to levels that were present in
2003 [36]. This rebound in infection rates underscores the
importance of maintaining the MDA schedule and ensuring
compliance in the population.
The LF elimination program in Leogane has been ongoing for
eight years. The program has been successful in reducing MF and
antigen rates from baseline levels over the course of seven rounds
of MDA. Despite these achievements, and despite reaching the
WHO benchmarks for success, there is ongoing transmission of LF
in Leogane commune. It appears that one of the main contributors
to this transmission is individuals who have never participated in
the MDA. They may provide a pool of infection by which the
mosquitoes become infected and the parasite is transmitted to
others. The reasons for noncompliance are not completely clear.
Also, noncompliance is one of many factors that could play a part
in transmission. Other factors include vector density, a missed
round of MDA, and the heterogeneity of transmission. New tools
and approaches are needed in this environment in addition to the
further studies recommended above. Increased health education
and awareness campaigns may improve compliance. The addition
of vector control methods such as insecticide treated bed nets
could provide the extra push needed to stop transmission. It is also
possible that DEC-fortified salt represents a programmatic
alternative that should be re-visited. The incorporation of new
tools should be investigated and implemented so that the program
in Haiti can proceed toward elimination. The situation in Haiti is
not dissimilar to that found in other parts of the world. Haiti can
be used as a model for LF elimination in areas of high infection
prevalence and high vector pressure. Understanding obstacles and
solutions from the program in Haiti could be helpful for
elimination programs in other countries.
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